Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CTI BioPharma appoints Alan Burnett lead, myeloid diseases

This article was originally published in Scrip

Executive Summary

CTI BioPharma has named Dr Alan K Burnett therapeutic area lead for myeloid disease. Dr Burnett was most recently professor and head of the department of hematology in the Institute of Cancer and Genetics at Cardiff University. He will be responsible for creating and implementing the strategic development program for CTI's compounds in myeloid malignancies with a major focus on supplementing the company's current late-stage development programs in chronic myeloproliferative diseases and international development programs in other myeloid malignancies such as acute myeloid leukemias and myelodysplasia.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts